1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Pharma-Patient Engagement: insights from patient opinion leaders




TPatients and Pharma want the same thing, but for different reasons. Patients want access, support and information about the latest drugs while Pharma needs market access for sales and profits that will to fund more research. So, they are natural bedfellows....?

Patient pressure and influence across the range of Pharma's activities is growing. While Patient Advocacy Groups are well established, there is a new breed of patient, empowered by the digital revolution, and with access to a wide-range of clinical and health data. These advocates share information and experiences with fellow patients, are informed about their condition, keen to take an informed part in their diagnosis and treatment, and are no longer willing to abdicate decision-making to health professionals.

Collectively, they have political weight, independence and a high social profile: so what do patients want – and expect – from Pharma?

Talking the talk

For its part, Pharma speaks the language of patient-centricity but doesn't always deliver. Bound by regulations in many countries limiting what can, and cannot, be communicated to patients or put in the public domain, industry has struggled to square demands for more openness with regulatory regimes that actively limit its ability to communicate with end-user customers. That could be a generous interpretation: perhaps getting too close to patients presents unacceptable risk to reputation, independence, and the prevailing business model.

Whatever Pharma does, it will meet with concern that when profit is part of the health equation, then its motives can be questioned. The funding of patient groups and related patient focused initiatives leaves Pharma open to the accusation that by encouraging "pester power" and patient pressure on health payers and Health-Technology Assessment bodies, it can achieve what it is unable to do through normal regulatory channels: encourage reimbursement and product uptake while driving sales.

Time to catch up

With the community and voice the internet has given patients, demand for information and dialogue is developing rapidly. The industry's response – whether by choice or regulatory burden – has not. If the common aims of patients and Pharma are to be truly mutually beneficial, the industry has to up its patient–relations game.







Essential insight in this new report: Pharma-Patient Engagement

This closely argued and concise management report from FirstWord combines keen market observations with the insights of leading players in patients groups. It presents a compelling analysis of the issues and examines key drivers such as:

Understanding patient needs and which support services mean most to them
How patient groups and industry can best collaborate to achieve common goals
Understanding which digital communication channels work best, and what pitfalls to avoid
What industry can do to counter the often cynical light it is seen in
How engaging with patient groups can lead to better clinical-research design and outcomes
The need to take a positive, open role in the patient information debate and assess the benefits of getting it right




For senior management, marketing and communication executives, this report is a timely reminder that industry must do more to harness and engage with the rapidly growing power of the patient.

Insights from the report

"Provide the patient groups with independent funding to do what patients really need, instead of doing your own programmes and failing on their compliance, restrictions and barriers. Rather than spending so much money on these kinds of single-sponsor awareness programmes, why doesn't industry set up a fund to support organizations with core funding, removing any suspicion of undue influence?" Jan Geissler, cancer survivor, patient advocate and Director of the European Patients Academy on Therapeutic Innovation (EUPATI)

"I would say from this point onwards, pharma should expect to see much more feedback and much more pressure from patient-driven social media platforms, patient groups, around what they do, how they act, their models, their pricing and so on, and as a result will be forced to become more transparent and to justify things much more than they have been in the past," Eric Low, Chief Executive, Myeloma UK

"We patients want to have the keys to the car. We patients want to be in control of our own destiny with the pharmaceutical industry, with hospitals – with physicians truly being our consultants in an adult-to-adult relationship, not a parent/child relationship." Andrew Schorr, patient advocate and founder of Patient Power LLC

"It's always better to have support from as many companies as possible. Otherwise, the perception is that you're in the pocket of one company." Lizzie Graham, Director of Fundraising and Global Communications, the European Parkinson's Disease Association












Use this report to:

Understand how the patient/Pharma relationship will be critical in the future
Define what patients expect from Pharma
Know how social media is changing the face of patient power and communication
Capitalise on the benefits of working effectively with patient groups for common aims
Communicate key data and information effectively in a controlling regulatory environment

Experts Interviewed
Ilaria Passarani, head of the Food and Health Department, European Consumer Organisation (BEUC)
Andrew Schorr, patient advocate and founder of Patient Power LLC
Lizzie Graham, Director of Fundraising and Global Communications, the European Parkinson's Disease Association (EPDA)
Jan Geissler, patient advocate and Director of the European Patients Academy on Therapeutic Innovation (EUPATI)
Drew Lindon, Head of Policy and Campaigns, Prostate Cancer UK
Eric Low, Chief Executive, Myeloma UK
Michael Seres, patient advocate





Table Of Contents

Pharma-Patient Engagement: insights from patient opinion leaders
1.Executive summary
2.Empowered, aware patients
3.The pharma-patient relationship
3.1.Overlapping agendas in healthcare
3.2.Access to medicines
3.4.Communality of interests between patients and industry
3.5.Clinical-trial data transparency
3.6.Patient organisation fears of co-option
3.7.The effect of corporate reputation on relationships
3.8.Financial influence on patient groups
3.9.Emphasis on transparency
4.Programme and funding challenges
5.Recognise the interests of various stakeholders
5.1.Market conditions count
5.2.The call for free and frank discussion
5.3.Underlying concerns about the relationship
5.4.A mutually beneficial overlap of interests
6.Patient-centric medicines
6.1.Clinical-trial recruitment
6.2.Remodelling the interface between patients and industry
6.3.What do patients want?
6.4.Understanding the patient body
7.The impact of digital
7.1.Reaching beyond patient organisations
7.2.AllTrials and transparency
7.3.The business of pharmaceuticals
7.4.Pharma's social media lag
7.5.The patient thirst for information
7.6.The internet of things
7.7.The role of medical apps
7.8.Game-changing media
7.9.Pharma's reluctance to engage with patients
7.10.A new sphere of influence created by patient advocates online
8.The dynamics of patient empowerment and market change
8.1.does industry fit in?
8.2.Information needs beyond benefit-risk
8.3.Patients want information, not promotion
8.4.A relationship based on trust
8.5.Differences of interpretation can lead to confusion
8.6.Using third parties to provide information
9.How to engage with patient groups
9.1.You have to let go of the marketing
9.2.Information and engagement
9.3.A contribution to life and lifestyle
9.4.A conversation of equals
9.5.Talking and listening are both important
9.6.It comes back to trust
9.7.Addressing patient needs
9.8.Engaging early in RandD
9.9.Engaging with patients from top to bottom
10. Actively involving patients in RandD
10.1.Case study: the EUPATI project
10.2.Inolvement in RandD is selective
10.3.More expertise is needed
11.Case study: EPDA encourages national engagement
12.Conclusion: stepping up to the plate

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Hematological Cancers: Analytical Tool

Hematological Cancers: Analytical Tool

  • $ 11505
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Drugs and Diagnostics for Hematological Disorders: Global Markets

Drugs and Diagnostics for Hematological Disorders: Global Markets

  • $ 6650
  • Industry report
  • September 2016
  • by BCC Research

Use this report to: - Receive detailed information regarding screening, testing and treatment options for hematological disorders and blood cancer. - Learn about the types of diagnostic and treatment ...

Lung Cancer: Analytical Tool

August 2016 $ 8096

Ovarian Cancer: Analytical Tool

August 2016 $ 8096

Renal Cancer: Analytical Tool

August 2016 $ 8096

Bladder Cancer: Analytical Tool

August 2016 $ 8096

Download Unlimited Documents from Trusted Public Sources

Therapy and Hormone Market in South Korea

  • December 2016
    4 pages
  • Therapy  

    Hormone  

    Cancer  

  • South Korea  

View report >

Cancer Statistics in the UK

  • December 2016
    20 pages
  • Cancer  

  • United Kingdom  

    Europe  

View report >

Cancer Statistics in the US and South Korea

  • November 2016
    2 pages
  • Cancer  

  • United States  

    South Korea  

View report >

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.